Lucas Silva Franco

Dr. Lucas Silva Franco

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
Carlos FragaCarlos Fraga
Carlos Fraga
One of the key scientific aspects of small-molecule drug discovery and development is the analysis of the relationship between its chemical structure and biological activity. Understanding the effects that lead to significant changes in biological activity is of paramount importance for the rational design and optimization of bioactive molecules. The “methylation effect”, or the “magic methyl” effect, is a factor that stands out due to the number of examples that demonstrate profound changes in either pharmacodynamic or pharmacokinetic properties. In many cases, this has been carried out rationally, but in others it has been the product of serendipitous observations. This paper summarizes recent examples that provide an overview of the current state of the art and contribute to a better understanding of the methylation effect in bioactive small-molecule drug candidates.

29 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
LDLuan Diniz
Luan Diniz
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
FGFlávia Carvalho Alcantara Gomes
Flávia Carvalho Alcantara Gomes
Histone deacetylases (HDACs) are key epigenetic regulators that influence chromatin remodeling, gene expression, and cellular plasticity in the central nervous system (CNS). This review provides a comprehensive overview of the classification and functional diversity of HDACs, with particular emphasis on their roles in neural progenitor cells, mature neurons, and glial populations. In neural stem and progenitor cells, HDACs modulate neurogenesis, fate specification, and lineage commitment. In differentiated neurons, HDACs govern synaptic plasticity, memory formation, and survival. In glial cells, including astrocytes and microglia, HDACs orchestrate inflammatory responses, redox balance, and metabolic adaptations. We further examine the dysregulation of HDAC expression and activity in major neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Evidence from human post-mortem brain studies reveals region- and isoform-specific alterations in HDAC expression, which are closely associated with cognitive decline, mitochondrial dysfunction, and neuroinflammation. Preclinical studies support the use of HDAC inhibitors (HDACi) as neuroprotective agents, capable of restoring acetylation homeostasis, reducing neuroinflammation, and improving neuronal function. Given the relevance of HDACi, we summarize current clinical studies assessing the safety of these compounds in the context of tumor biology, as well as their potential future applications in neurodegenerative diseases. Together, this review underscores the dual significance of HDACs as biomarkers and therapeutic targets in the context of CNS disorders.

2 November 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
RMRodolfo C. Maia
Rodolfo C. Maia
EBEliezer J Barreiro
Eliezer J Barreiro
A SARS-CoV-2 main protease (MPRO) inhibitor was discovered employing molecular docking and a fragment-based pharmacophore model as virtual screening strategies.

6 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
BJBárbara da Silva Mascarenhas de Jesus
Bárbara da Silva Mascarenhas de Jesus
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
Carlos FragaCarlos Fraga
Carlos Fraga
This work examines the current landscape of drug discovery and development, with a particular focus on the chemical and pharmacological spaces. It emphasizes the importance of understanding these spaces to anticipate future trends in drug discovery. The use of cheminformatics and data analysis enabled in silico exploration of these spaces, allowing a perspective of drugs, approved drugs after 2020, and clinical candidates, which were extracted from the newly released ChEMBL34 (March 2024). This perspective on chemical and pharmacological spaces enables the identification of trends and areas to be occupied, thereby creating opportunities for more effective and targeted drug discovery and development strategies in the future.

30 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
LDLuan Diniz
Luan Diniz
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
MSMichele Siqueira
Michele Siqueira
FGFlávia Carvalho Alcantara Gomes
Flávia Carvalho Alcantara Gomes
Histone deacetylases (HDACs) are crucial enzymes involved in the regulation of gene expression through chromatin remodeling, impacting numerous cellular processes, including cell proliferation, differentiation, and survival. In recent years, HDACs have emerged as therapeutic targets for neurodegenerative diseases (NDDs), such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, given their role in modulating neuronal plasticity, neuroinflammation, and neuronal survival. HDAC inhibitors (HDACi) are small molecules that prevent the deacetylation of histones, thereby promoting a more relaxed chromatin structure and enhancing gene expression associated with neuroprotective pathways. Preclinical and clinical studies have demonstrated that HDACi can mitigate neurodegeneration, reduce neuroinflammatory markers, and improve cognitive and motor functions, positioning them as promising therapeutic agents for NDDs. Given the complexity and multifactorial nature of NDDs, therapeutic success will likely depend on multi-target drugs as well as new cellular and molecular therapeutic targets. Emerging evidence suggests that HDACi can modulate the function of astrocytes, a glial cell type critically involved in neuroinflammation, synaptic regulation, and the progression of neurodegenerative diseases. Consequently, HDACi targeting astrocytic pathways represent a novel approach in NDDs therapy. By modulating HDAC activity specifically in astrocytes, these inhibitors may attenuate pathological inflammation and promote a neuroprotective environment, offering a complementary strategy to neuron-focused treatments. This review aims to provide an overview of HDACs and HDACi in the context of neurodegeneration, emphasizing their molecular mechanisms, therapeutic potential, and limitations. Additionally, it explores the emerging role of astrocytes as targets for HDACi, proposing that this glial cell type could enhance the efficacy of HDACs-targeted therapies in NDD management.

23 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GBGisele Barbosa
Gisele Barbosa
LGLuis Gabriel Valdivieso Gelves
Luis Gabriel Valdivieso Gelves
CCCaroline Marques Xavier Costa
Caroline Marques Xavier Costa
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
JLJoão Alberto Lins de Lima
João Alberto Lins de Lima
Lidia Moreira LimaLidia Moreira Lima
Lidia Moreira Lima
Combretastatin A-4 (CA-4, 1) is an antimicrotubule agent used as a prototype for the design of several synthetic analogues with anti-tubulin activity, such as LASSBio-1586 (2). A series of branched and unbranched homologs of the lead-compound 2, and vinyl, ethinyl and benzyl analogues, were designed and synthesized. A comparison between the cytotoxic effect of these homologs and 2 on different human tumor cell lines was performed from a cell viability study using MTT with 48 h and 72 h incubations. In general, the compounds were less potent than CA-4, showing CC50 values ranging from 0.030 μM to 7.53 μM (MTT at 72 h) and 0.096 μM to 8.768 μM (MTT at 48 h). The antimitotic effect of the target compounds was demonstrated by cell cycle analysis through flow cytometry, and the cellular mechanism of cytotoxicity was determined by immunofluorescence. While the benzyl homolog 10 (LASSBio-2070) was shown to be a microtubule stabilizer, the lead-compound 2 (LASSBio-1586) and the methylated homolog 3 (LASSBio-1735) had microtubule destabilizing behavior. Molecular docking studies were performed on tubulin protein to investigate their binding mode on colchicine and taxane domain. Surprisingly, the benzyl homolog 10 was able to modulate EGFR phosphorylate activity in a phenotypic model. These data suggest LASSBio-2070 (10) as a putative dual inhibitor of tubulin and EGFR. Its binding mode with EGFR was determined by molecular docking and may be useful in lead-optimization initiatives.